Immunovaccine – cancer immunotherapies

Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on a patented formulation providing controlled and prolonged exposure of antigens and adjuvant to the immune system : DepoVax.

Immunovaccine – cancer immunotherapies

IMV immunovaccine

Immunovaccine is a clinical-stage vaccine development company focused on advancing its patented DepoVax vaccine adjuvanting platform for infectious disease, cancer therapy and animal health. DepoVax is a patented vaccine delivery formulation providing controlled and prolonged exposure of antigens and adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the capability for single-dose effectiveness. DepoVax platform possesses huge flexibility, thus allowing it to work with a broad range of target antigens in various therapeutic applications. By targeting early-stage and minimal disease, DepoVax technology supports the immune system by combining with effective immunomodulators and targeting validated, disease-specific antigens capable of targeting tumors and not healthy cells.

DepoVax’s ability to generate fast, strong and long-lasting immune responses against a wide range of targets is already applied to several immunotherapies. Indeed, DepoVax serves as the foundation for DepoVax’s broad product pipeline, including two clinical-stage cancer immunotherapies (DPX-Survivac and DPX-0907). DPX-Survivac successfully completed Phase I study and demonstrated a strong and sustained T cell reponses. DPX-Survivac is now entering large randomized controlled Phase II clinical trials in ovarian cancer and glioblastoma. Immunovaccine’s pipeline also includes a broad range of infectious diseases programs (like respiratory syncytial virus (RSV) and anthrax) as well as animal health vaccine applications.

Immunovaccine is a biotech company based in Halifax (Canada). Partnerships represent an essential element of Immunovaccine’s business strategy, including partnership with many leaders in their respective areas of focus (NIH, Zoetis, etc…).

More about Immunovaccine :

Immunovaccine – cancer immunotherapies – infectious disease vaccines – immune system – DepoVax – adjuvanting platform – DPX-Survivac – – Survivac

Immunovaccine – cancer immunotherapy – infectious disease vaccine – antigen – adjuvant – vaccine delivery formulation – immunomodulator – respiratory syncytial virus – RSV – anthrax – NIH – Zoetis